Statin Therapy
Top in cardiology: FDA OKs second pulsed field ablation system; BP drug reduces anxiety
The FDA approved a second pulsed field ablation system for the treatment of paroxysmal atrial fibrillation based on real-world data from the MANIFEST-17K registry and positive findings from the pivotal ADVENT clinical trial.
Updates in women’s heart health: low statin use; women in CV fellowships; and more
The first Friday in February is Wear Red Day. In support of increasing awareness of women’s heart health, Healio | Cardiology Today compiled a list of recent news and updates on women and CVD research.
Healthy lifestyle paired with statins may boost life expectancy
The combination of statin use and healthy lifestyle was linked to a 30% lower risk for all-cause death and 44% reduced risk for CV death in people at high CV risk vs. those not taking statins with an unhealthy lifestyle, data show.
Top in cardiology: Sibling death linked to heart disease; hybrid vs. in-person care model
People who experienced the death of a sibling during childhood or early adulthood had a 17% greater risk for CVD, according to recent study findings.
Statin benefits after pediatric heart transplant uncertain
Data from a large pediatric heart transplant recipient database suggest initiating statin therapy after transplant has no benefit on graft survival or freedom from cardiac allograft vasculopathy compared with no statin use.
Statins could mitigate clotting risk in women at menopausal age on hormone therapy
Statin therapy could lower the odds of blood clot formation conferred by hormone therapy in perimenopausal women, according to a case-control study published in JAMA Network Open.
At Issue: The implications of SELECT on CVD prevention in high-risk patients with obesity
The SELECT trial, which showed semaglutide, a GLP-1 receptor agonist also approved for diabetes, reduced CV events in people with overweight/obesity and CVD but no diabetes, was one of the most important developments in cardiology in 2023.
Targeting obesity may be ‘highly effective strategy’ for treating HFpEF, ASCVD
Findings from two cardiovascular outcome trials revealed that targeting obesity could become a major focus for treating cardiovascular disease and heart failure with preserved ejection fraction in the future, according to a speaker.
Race, comorbidities impact mortality risk with severe hypercholesterolemia
Electronic records data show race, sex, age and comorbidities influence mortality risk for adults with severe hypercholesterolemia and that one in four of these high-risk patients is not prescribed statin therapy.
Most adults eligible for statins do not receive them
Most adults who are eligible for statin use to prevent CVD are not receiving them, according to a study published in Annals of Internal Medicine.